10 Best NASDAQ Growth Stocks to Buy for the Next 3 Years

8. Corcept Therapeutics Incorporated (NASDAQ:CORT)

3-Year Revenue CAGR: 21.71%

Number of Hedge Fund Holders: 33

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best NASDAQ growth stocks to buy for the next 3 years. On June 24, Corcept Therapeutics announced positive results from the CATALYST trial of Korlym (mifepristone). The data was presented at the American Diabetes Association’s 85th Scientific Sessions and also published in Diabetes Care. It showed that Korlym improved glucose control in patients with hypercortisolism (Cushing’s syndrome) and difficult-to-control type 2 diabetes.

The trial met its primary endpoint, as patients receiving Korlym experienced a 1.47% decrease in HbA1c from baseline, as compared to a 0.15% decrease in the placebo group. Those on a 900mg dose saw a 2.01% HbA1c improvement. Beyond blood sugar, Korlym also led to reductions in body weight (by 5.1 kg) and waist circumference (by 5.1 cm), even as patients reduced or stopped other glucose-lowering medications.

The CATALYST trial is the largest to date investigating hypercortisolism in difficult-to-control type 2 diabetes. Its initial phase screened 1,057 patients and found that 24% had hypercortisolism, which made them eligible for the treatment phase.

Corcept Therapeutics Incorporated (NASDAQ:CORT) discovers and develops medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the US.